Cardiol Therapeutics President and CEO, David Elsley
PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis
19. Dezember 2024 08:30 ET | PRISM MarketView
PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™